Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.43) per share. This is a 49.41 percent increase over losses of $(0.85) per share from the same period last year.
Nexalin Technology Announces Results Of Clinical Study Validating Its Gen-2 tACS Device For Reducing Pain Among Veterans With Mild Traumatic Brain Injury At University Of California, San Diego
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control groupThe data supports the Company's strategy to offer military and civilian physicians a
